Silent brain infarction (SBI) has been considered as a subclinical risk factor for symptomatic possible future stroke. We investigated the association between serum inflammatory markers and SBI. Patients (n = 54) diagnosed with SBI as the study group and 52 individuals as the control group were included in this study. Silent brain infarction is defined as a hyperintense lesion that was ≥3 mm in 1 dimension on fluid-attenuated inversion recovery T2-weighted magnetic resonance image, if the patient had normal neurological examination or had an abnormality that was not consistent with the brain lesion locations, after being evaluated by a neurologist. Serum endocan levels (P = .036) and high-sensitivity C-reactive protein (hsCRP; P = .022) were significantly higher in patients with SBI than the controls. Pentraxin 3, erythrocyte sedimentation rate, white blood count, lymphocyte, monocyte, neutrophil, low-density lipoprotein, and triglyceride levels were not significantly different when comparing the groups with and without SBI. There was a significant correlation (r = −0.196; P = .16) between hsCRP and endocan levels in the SBI group. Endocan, a novel biomarker of endothelial pathology, was significantly increased in patients with SBI and may be useful to predict the future risk of stroke.
DebetteSBeiserADeCarliC, et al.Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41: 600–6.
4.
KawamuraTUmemuraTKanaiA, et al.Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism. 2006;55:461e6.
5.
LimJSKwonHM. Risk of “silent stroke” in patients older than 60 years: risk assessment and clinical perspectives. Clin Interv Aging. 2010;5:239–51.
6.
UmemuraTKawamuraTUmegakiH, et al.Endothelial and inflammatory markers in relation to progression of ischaemic cerebral small-vessel disease and cognitive impairment: a 6-year longitudinal study in patients with type 2 diabetes mellitus. J Neurol Neurosurg Pshychiatry. 2011;82:1186–94.
7.
FanningJPSee HoeLEPassmoreMR, et al.Differential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction. Ther Adv Neurol Disord. 2018;11:1756286418759493.
8.
BalamirIAtesITopcuogluC, et al.Association of Endocan, Ischemia-Modified Albumin, and hsCRP Levels With Endothelial Dysfunction in Type 2 Diabetes Mellitus. Angiology. 2018;69:609–16.
9.
SarrazinSAdamELyonM, et al.Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765:25–37.
10.
LeeWKuSKKimSW, et al.Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229: 620–30.
11.
HeXWKeSFBaoYY, et al.Serum levels of endocan and endoglin are associated with large-artery atherosclerotic stroke. Clin Chim Acta. 2018:478;157–61.
12.
UstyolAAycan UstyolEGurdolF, et al.P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2017;77:205–9.
13.
De Freitas CairesNGaudetAPortierLTsicopoulosAMathieuDLassalleP. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. Crit Care. 2018;22:280.
14.
BechardDMeigninVScherpereelA, et al.Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37: 417–25.
15.
CimenTEfeTHAkyelA, et al.Human endothelial cell-specific molecule-1 (endocan) and coronary artery disease and microvascular angina. Angiology. 2016;67:846–53.
16.
IcliACureECureMC, et al.Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Angiology. 2016;67:749–55.
17.
BaltaSMikhailidisDPDemirkolS, et al.Endocan and atherosclerosis. Angiology. 2015;66:490.
18.
ChenDWWangYXShiJ, et al.Multiple Silent Brain Infarcts Are Associated with Severer Stroke in Patients with First-Ever Ischemic Stroke without Advanced Leukoaraiosis. J Stroke Cerebrovasc Dis. 2017;26:1988–95.
19.
WaldsteinSRSiegelELLefkowitzD, et al.Stress-induced blood pressure reactivity and silent cerebrovascular disease. Stroke. 2004;35:1294–8.
20.
GiannopoulosAKakkosSAbbottA, et al.Long-term Mortality in Patients with Asymptomatic Carotid Stenosis: Implications for Statin Therapy. Eur J Vasc Endovasc Surg. 2015;50:573–82.
21.
SmithEESaposnikGBiesselsGJ, et al.Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48: 44–71.
22.
MarkusHSHuntBPalmerK, et al.Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: Longitudinal results of the Austrian stroke prevention study. Stroke. 2005;36:1410–4.
23.
HanJHWongKSWangYY, et al.Plasma level of sICAM-1 associated with extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg. 2009; 111: 847-51.
24.
LowAMakERoweJB, et al.Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev. 2019;53:100916.
25.
PogessiAPasiMPesciniF, et al.Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review. J Cereb Blood Flow Metab. 2016;36:72–94.
26.
HoshiTKitagawaKYamagamiH, et al.Relations of serum high sensitivity C-reactive protein and interleukin-6 levels with silent brain infarction. Stroke. 2005; 36: 768–72.
27.
RouhlRPDamoiseauxJGLodderJ, et al.Vascular inflammation in cerebral small vessel disease. Neurobiol Aging. 2012; 33: 1800–06.
28.
BaltaIBaltaSKoryurekOM, et al.Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014;70:291–6.
29.
BaltaSMikhailidisDPDemirkolS, et al.Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65:773–7.
30.
BaltaIBaltaSDemirkolS, et al.Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169:1066–70.
